Aurora Cannabis (ACB) AI Stock Analysis

• Market Cap: $368.41M
• Dividend Yield: N/A
• Average Volume (3M): 567.75K
• Price to Earnings (P/E): 112.3
• Beta (1Y): 2.39
• Revenue Growth: 26.98%
• EPS Growth: N/A
• Country: CA
• Employees: 1,073
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.35
• Shares Outstanding: 56,246,403
• 10 Day Avg. Volume: 413,120
• 30 Day Avg. Volume: 567,754
• PEG Ratio: -2.61
• Price to Book (P/B): 0.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -123.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.97
• Price Target Upside: 5.19% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 51 Neutral
• Price Target: C$6.50 ▼(-1.96%Downside)

Aurora Cannabis shows potential with recent profitability and strategic international growth. However, high valuation, inconsistent revenue, and cash flow challenges weigh on the score. The positive outlook from their earnings call and corporate event achievements provide optimism, though financial performance remains a significant concern.

Positive Factors

Financial Stability

The company's balance sheet offers optionality even in tough conditions.

Market Potential

A federal re-scheduling in the U.S. should provide benefits including increased research, lower stigma, improve access to capital, and unlock the world's biggest addressable cannabis market.

Strategic Shift

ACB has turned over a proverbial new leaf following the reset in the cannabis industry, now with a focus on responsible growth.

Negative Factors

Industry Risks

There are lingering risks in the emerging cannabis industry including rampant illicit markets, limited insurance coverage, and unpredictable path to further de-regulation.

Operational Challenges

There are administration delays in settlement payments.

Aurora Cannabis Business Overview & Revenue Model

Company Description

Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

How the Company Makes Money

Aurora Cannabis generates revenue primarily through the sale of cannabis products for both medical and recreational purposes. The company's revenue streams include direct sales to consumers through various retail channels, wholesale distribution to other licensed producers and retailers, and sales in international markets where cannabis is legal. Aurora also partners with other companies to enhance its product offerings and expand its market reach. Additionally, the company invests in research and development to innovate and improve its product portfolio, which can drive higher sales and customer loyalty. Aurora's earnings are influenced by factors such as regulatory changes, consumer preferences, and market competition.

Aurora Cannabis Financial Statement Overview

Summary

Aurora Cannabis has made strides towards profitability with a positive net income and improved operating cash flow. However, challenges such as inconsistent revenue growth, low margins, and negative free cash flow persist.

Income Statement

Aurora Cannabis has shown a recent improvement in profitability with a positive net income for the latest period, reflecting a significant turnaround from previous losses. However, the revenue growth has been inconsistent over the past years, and margins remain low with a gross profit margin of 54.64% and a net profit margin of 0.46% for the latest period. The EBIT and EBITDA margins reflect operating challenges, despite the latest EBITDA turning positive.

Balance Sheet

The company has a solid equity position with a debt-to-equity ratio of 0.18, suggesting limited leverage risk. However, the equity ratio is 66.50%, indicating a reasonable balance of equity relative to assets. Return on equity remains low at 0.28%, highlighting challenges in generating returns for shareholders.

Cash Flow

Aurora Cannabis shows improvement in operating cash flow, but free cash flow remains negative, indicating ongoing cash flow challenges. The operating cash flow to net income ratio is 10.06, suggesting that operating cash generation is improving relative to reported earnings, but the free cash flow to net income ratio is negative, emphasizing cash constraints.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	343.29M	270.28M	233.29M	221.34M	245.25M
Gross Profit	187.61M	131.46M	-64.36M	21.23M	-21.56M
EBITDA	51.35M	-12.34M	-210.74M	-1.55B	-535.28M
Net Income	1.59M	-69.33M	-265.33M	-1.72B	-693.63M
Balance Sheet
Total Assets	852.67M	838.67M	926.32M	1.08B	2.60B
Cash, Cash Equivalents and Short-Term Investments	138.47M	117.47M	300.84M	439.14M	425.21M
Total Debt	104.58M	104.79M	227.52M	269.49M	399.55M
Total Liabilities	244.07M	236.80M	409.19M	422.00M	567.03M
Stockholders Equity	567.17M	559.77M	486.08M	661.84M	2.04B
Cash Flow
Free Cash Flow	-2.85M	-85.46M	-127.95M	-142.48M	-263.66M
Operating Cash Flow	16.00M	-68.51M	-115.82M	-110.27M	-210.58M
Investing Cash Flow	-14.33M	-5.49M	-27.29M	-36.17M	-26.91M
Financing Cash Flow	-116.00K	-47.92M	-56.48M	147.78M	521.95M

Aurora Cannabis Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.63
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ACB, the sentiment is Positive. The current price of 6.63 is above the 20-day moving average (MA) of 6.26, below the 50-day MA of 6.82, and below the 200-day MA of 6.71, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.69 is Neutral, neither overbought nor oversold. The STOCH value of 62.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ACB.

Aurora Cannabis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACB	51 Neutral	$368.41M	112.35	3.05%	―	26.98%	―
Sector *	46 Neutral	C$201.68M	-3.23	-23.14%	1.87%	20.75%	-0.36%
CGC	―	$230.50M	―	-122.10%	―	―	―
OGI	―	$203.35M	22.50	4.76%	―	―	―
CRLBF	―	$276.92M	―	-17.34%	―	―	―
TSND	62 Neutral	C$196.10M	―	-38.89%	―	-6.80%	11.94%
CBSTF	―	$166.91M	―	-554.70%	―	―	―

Aurora Cannabis Corporate Events

Aurora Cannabis Schedules Q1 2026 Financial Results Conference Call

Aurora Cannabis announced it will host a conference call on August 6, 2025, to discuss its financial results for the first quarter of 2026. The call will be led by CEO Miguel Martin and CFO Simona King, and it aims to provide insights into the company’s financial performance and strategic direction. This announcement is significant as it reflects Aurora’s ongoing commitment to transparency and engagement with investors, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.

Aurora Cannabis Achieves EU-GMP Certification for Distribution Centre

Aurora Cannabis Inc. has achieved its first-ever EU-GMP certification for its dedicated distribution centre in Brampton, Ontario, enhancing its international export capabilities. This certification, which aligns with European Union standards, allows Aurora to optimize its global supply chain and ensure consistent access to high-quality medical cannabis for patients worldwide, reinforcing its position as a leading exporter in the industry.

The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.

Aurora Cannabis Announces Shareholder Meeting Details

Aurora Cannabis Inc. has announced the availability of its management information circular for the upcoming annual general and special meeting of shareholders. The meeting, scheduled for August 8, 2025, will be held virtually, allowing shareholders worldwide to participate. Aurora’s board recommends voting in favor of all director nominees and meeting resolutions, emphasizing the importance of shareholder participation. This announcement underscores Aurora’s commitment to transparent governance and active shareholder engagement, potentially impacting its industry positioning and stakeholder relations.

The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.

Aurora Cannabis to Discuss Fiscal Year 2025 Results in Upcoming Investor Call

Aurora Cannabis announced it will host a conference call on June 18, 2025, to discuss its fourth quarter and fiscal year 2025 financial results. This announcement highlights the company’s commitment to transparency and engagement with investors, which could impact its market positioning and stakeholder relations positively.

The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.